Search

Your search keyword '"Chymases antagonists & inhibitors"' showing total 124 results

Search Constraints

Start Over You searched for: Descriptor "Chymases antagonists & inhibitors" Remove constraint Descriptor: "Chymases antagonists & inhibitors"
124 results on '"Chymases antagonists & inhibitors"'

Search Results

1. Substrate specificity of human chymotrypsin-like protease (CTRL) characterized by phage display-selected small-protein inhibitors.

2. Mast cells in liver disease progression: An update on current studies and implications.

3. Chymase as a Novel Therapeutic Target in Acute Pancreatitis.

4. Role of chymase in blood pressure control, plasma and tissue angiotensin II, renal Haemodynamics, and excretion in spontaneously hypertensive rats.

5. Combined computational and cellular screening identifies synergistic inhibition of SARS-CoV-2 by lenvatinib and remdesivir.

6. Chymase inhibition: A key factor in the anti-inflammatory activity of ethanolic extracts and spilanthol isolated from Acmella oleracea.

7. Postoperative Adhesion Prevention Using a Biodegradable Temperature-Responsive Injectable Polymer System and Concomitant Effects of the Chymase Inhibitor.

8. Phytochemicals against SARS-CoV as potential drug leads.

9. Mast Cell Degranulation Increases Mouse Mast Cell Protease 4-Dependent Vasopressor Responses to Big Endothelin-1 But Not Angiotensin I.

10. Mast Cell Chymase and Kidney Disease.

11. Chymase as a Possible Therapeutic Target for Amelioration of Non-Alcoholic Steatohepatitis.

12. Mechanism of Albuminuria Reduction by Chymase Inhibition in Diabetic Mice.

13. Amblyomma americanum serpin 41 (AAS41) inhibits inflammation by targeting chymase and chymotrypsin.

14. Effects of the chymase inhibitor fulacimstat on adverse cardiac remodeling after acute myocardial infarction-Results of the Chymase Inhibitor in Adverse Remodeling after Myocardial Infarction (CHIARA MIA) 2 trial.

15. Potential anti-SARS-CoV-2 drug candidates identified through virtual screening of the ChEMBL database for compounds that target the main coronavirus protease.

16. Binding Loop Substitutions in the Cyclic Peptide SFTI-1 Generate Potent and Selective Chymase Inhibitors.

17. Novel Insight into the in vivo Function of Mast Cell Chymase: Lessons from Knockouts and Inhibitors.

18. Chymase inhibition retards albuminuria in type 2 diabetes.

19. Safety and Tolerability of the Chymase Inhibitor Fulacimstat in Patients With Left Ventricular Dysfunction After Myocardial Infarction-Results of the CHIARA MIA 1 Trial.

20. ASB17061, a novel chymase inhibitor, prevented the development of angiotensin II-induced abdominal aortic aneurysm in apolipoprotein E-deficient mice.

21. Structure-based virtual screening for novel chymase inhibitors by in silico fragment mapping.

22. Pharmacokinetics, Safety, and Tolerability of the Novel Chymase Inhibitor BAY 1142524 in Healthy Male Volunteers.

23. Comparison of a chymase inhibitor and hyaluronic acid/carboxymethylcellulose (Seprafilm) in a novel peritoneal adhesion model in rats.

24. Prospective single-arm observational study of human chymase inhibitor Polygonum hydropiper L in subjects with hypertension.

25. Searching for Chymase Inhibitors among Chamomile Compounds Using a Computational-Based Approach.

26. Chymase inhibitors for the treatment of cardiac diseases: a patent review (2010-2018).

27. Effects of the selective chymase inhibitor TEI-F00806 on the intrarenal renin-angiotensin system in salt-treated angiotensin I-infused hypertensive mice.

28. Modular design of optically controlled protein affinity reagents.

29. Multifunctional Role of Chymase in Acute and Chronic Tissue Injury and Remodeling.

30. Structure-based design, synthesis, and binding mode analysis of novel and potent chymase inhibitors.

31. Dual inhibition of cathepsin G and chymase reduces myocyte death and improves cardiac remodeling after myocardial ischemia reperfusion injury.

32. Characterization and comparison of recombinant honeybee chymotrypsin-like protease (HCLPase) expressed in Escherichia coli and insect cells.

33. Chymase inhibitor prevents the development and progression of non-alcoholic steatohepatitis in rats fed a high-fat and high-cholesterol diet.

34. Dissecting the role of mutations in chymase inhibition: Free energy and decomposition analysis.

35. Cloning a Chymotrypsin-Like 1 (CTRL-1) Protease cDNA from the Jellyfish Nemopilema nomurai.

36. Chymase inhibition protects diabetic rats from renal lesions.

37. In silico approach to find chymase inhibitors among biogenic compounds.

38. Interaction of human chymase with ginkgolides, terpene trilactones of Ginkgo biloba investigated by molecular docking simulations.

39. Improvement of cardiovascular remodelling by chymase inhibitor.

40. Chymase inhibitor TY-51469 in therapy of inflammatory bowel disease.

41. Depressor effect of chymase inhibitor in mice with high salt-induced moderate hypertension.

42. Chymase: a multifunctional player in pulmonary hypertension associated with lung fibrosis.

43. Effects of chymostatin, a chymase inhibitor, on blood pressure, plasma and tissue angiotensin II, renal haemodynamics and renal excretion in two models of hypertension in the rat.

45. Role of chymase in the local renin-angiotensin system in keloids: inhibition of chymase may be an effective therapeutic approach to treat keloids.

46. Finding off-targets, biological pathways, and target diseases for chymase inhibitors via structure-based systems biology approach.

47. Chymase inhibitor-sensitive synthesis of endothelin-1 (1-31) by recombinant mouse mast cell protease 4 and human chymase.

48. Fused-ring structure of decahydroisoquinolin as a novel scaffold for SARS 3CL protease inhibitors.

49. Chymase inhibition improves vascular dysfunction and survival in stroke-prone spontaneously hypertensive rats.

50. Chymase mediates injury and mitochondrial damage in cardiomyocytes during acute ischemia/reperfusion in the dog.

Catalog

Books, media, physical & digital resources